These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38307520)

  • 1. Aduhelm: Biogen abandons Alzheimer's drug after controversial approval left it unfunded by Medicare.
    Dyer O
    BMJ; 2024 Feb; 384():q281. PubMed ID: 38307520
    [No Abstract]   [Full Text] [Related]  

  • 2. Aduhelm, the Newly Approved Medication for Alzheimer Disease: What Epidemiologists Can Learn and What Epidemiology Can Offer.
    Glymour MM; Weuve J; Dufouil C; Mayeda ER
    Am J Epidemiol; 2022 Jul; 191(8):1347-1351. PubMed ID: 35388413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversial Approval of New Drug to Treat Alzheimer's Disease.
    Aschenbrenner DS
    Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aduhelm: The Best Hope for Alzheimer's Disease Patients or the Worst Decision the FDA Has Ever Made?
    Kurkinen M; Tran L
    J Alzheimers Dis; 2021; 84(3):969-971. PubMed ID: 34657888
    [No Abstract]   [Full Text] [Related]  

  • 5. Aducanumab Fails to Produce Efficacy Results Yet Obtains US Food and Drug Administration Approval.
    Angelo M; Ward L
    Popul Health Manag; 2021 Dec; 24(6):638-639. PubMed ID: 34516238
    [No Abstract]   [Full Text] [Related]  

  • 6. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
    Høilund-Carlsen PF; Alavi A
    J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aducanumab (Aduhelm) for Alzheimer's disease.
    Med Lett Drugs Ther; 2021 Jul; 63(1628):105-106. PubMed ID: 34543258
    [No Abstract]   [Full Text] [Related]  

  • 8. Ignoring the Experts: Implications of the FDA's Aduhelm Approval.
    Maulden A
    Am J Law Med; 2022 Mar; 48(1):108-133. PubMed ID: 35815585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aduhelm: Approval of Alzheimer's drug was highly unorthodox, finds report.
    Tanne JH
    BMJ; 2023 Jan; 380():6. PubMed ID: 36596575
    [No Abstract]   [Full Text] [Related]  

  • 10. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA.
    Karlawish J; Grill JD
    Nat Rev Neurol; 2021 Sep; 17(9):523-524. PubMed ID: 34267383
    [No Abstract]   [Full Text] [Related]  

  • 11. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    Schulman KA; Greicius MD; Richman B
    JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
    [No Abstract]   [Full Text] [Related]  

  • 12. Making the Case for the Accelerated Withdrawal of Aducanumab.
    Whitehouse PJ; Saini V
    J Alzheimers Dis; 2022; 87(3):999-1001. PubMed ID: 35491796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversial Alzheimer's drug approval could affect other diseases.
    Mullard A
    Nature; 2021 Jul; 595(7866):162-163. PubMed ID: 34193994
    [No Abstract]   [Full Text] [Related]  

  • 14. Making the Case for Accelerated Withdrawal of Aducanumab.
    Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L
    J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What to Know About the Alzheimer Drug Aducanumab (Aduhelm).
    Woloshin S; Kesselheim AS
    JAMA Intern Med; 2022 Aug; 182(8):892. PubMed ID: 35666531
    [No Abstract]   [Full Text] [Related]  

  • 16. Aducanumab for Alzheimer's disease: A regulatory perspective.
    Nisticò R; Borg JJ
    Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US FDA defends approval of Alzheimer's disease drug.
    Jaffe S
    Lancet; 2021 Jul; 398(10294):12. PubMed ID: 34217382
    [No Abstract]   [Full Text] [Related]  

  • 18. A carte blanche approval in Alzheimer's.
    Nat Biotechnol; 2021 Jul; 39(7):781. PubMed ID: 34183862
    [No Abstract]   [Full Text] [Related]  

  • 19. [Aducanumab approval for Alzheimer's disease in the USA: the surrender of science].
    Dal-Ré R
    Rev Neurol; 2021 Oct; 73(8):296-297. PubMed ID: 34617583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A contentious FDA ruling for Alzheimer's disease.
    The Lancet Neurology
    Lancet Neurol; 2021 Aug; 20(8):585. PubMed ID: 34237273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.